Listar por autor "Saunders, M. P."
Mostrando ítems 1-3 de 3
-
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Springer Nature, 2022-06-01) -
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study
Bordonaro, R.; Calvo, A.; Auriemma, A.; Hollebecque, Antoine; Rubovszky, G.; Saunders, M. P.; Argilés Martinez, Guillem; Tabernero Caturla, Josep (Elsevier, 2021-10) -
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Elsevier, 2020-09)